Dermata therapeutics announces exercise of warrants for $6.2 million in gross proceeds priced at-the-market under nasdaq rules

San diego, ca / access newswire / march 27, 2025 / dermata therapeutics, inc. (nasdaq:drma)(nasdaq:drmaw) ("dermata," or the "company"), a late-stage biotechnology company focused on the treatment of medical skin diseases and aesthetic applications, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase an aggregate of 4,834,470 shares of the company's common stock, having exercise prices of $1.58 and $4.91 per share, issued by dermata in september 2024 (with respect to 3,825,138 warrants) and may 2024 (with respect to 1,009,332 warrants), at a reduced exercise price of $1.284 per share. the shares of common stock issuable upon exercise of the warrants are registered pursuant to effective registration statements on form s-3 (file nos.
NDAQ Ratings Summary
NDAQ Quant Ranking